GLP-1s and Your 2026 Health Plan: The Employer Cost Guide
GLP-1s now hit 11.4% of employer claims. What covering weight-loss drugs really costs in 2026, the honest ROI evidence, and how benefits leaders manage the spend.
Manifold Health Clinical Team
Medically reviewed clinical content
Table of contents
Share
GLP-1 medications for diabetes and weight loss are now one of the largest single cost pressures on employer health plans — accounting for 11.4% of annual claims in 2026, up from 6.9% in 2023 (IFEBP via Becker's Payer). Most employers cover them in some form, most are not expanding that coverage, and nearly all are wrapping it in tighter rules to control the spend. The honest evidence on whether covering them saves an employer money is mixed and, in the near term, mostly points the other way. This guide lays out what coverage actually costs in 2026, what benefits leaders are doing about it, and where care navigation fits as the complement to a drug-only strategy.
The short version
GLP-1s are a top cost driver. They reached 11.4% of employer claims in 2026 (vs. 6.9% in 2023), and nearly 8 in 10 large employers say GLP-1s are increasing their health care costs (IFEBP/Becker's; Business Group on Health).
Coverage is common but flat. In 2026, 60% of employers cover GLP-1s for diabetes only and 36% cover them for both diabetes and weight loss — roughly unchanged from 2025 (IFEBP/Becker's).
Management, not expansion, is the story. Employers are leaning on utilization management — clinical-eligibility checks, prior authorization, program participation, and prescriber or formulary limits — rather than dropping or broadly expanding coverage (Business Group on Health).
The ROI is contested — grade it honestly. GLP-1s reliably raise total near-term spend; independent modeling and case studies show negative short-term ROI for most employers, while some longer-term analyses suggest cost moderation over multiple years (PHTI, Dec 2025).
A drug is not a program. Adherence, appropriate prescribing, and connecting members to obesity-medicine and metabolic care are what turn a covered prescription into a health outcome — which is where navigation earns its place.
Why GLP-1s are the defining employer benefits story of 2026
Employers are entering the 2027 planning cycle facing the worst affordability backdrop in over a decade. Mercer's national survey projects 2026 total health-benefit cost growth of 6.7%, pushing the average above $18,500 per employee — the largest increase in 15 years (Mercer). The Business Group on Health's survey of large employers projected a roughly 9% increase for 2026 before plan-design changes (Business Group on Health).
Prescription drugs are a leading reason. Rx spending rose about 9.4% among large employers in 2025, and GLP-1 medications are a central contributor (Mercer). Coverage kept climbing too: the share of large employers covering GLP-1s for weight loss reached 49% in 2025, up from 44% in 2024 (Mercer). And with once-daily oral GLP-1s now reaching the market alongside the injectables, the pool of people who can and want to start therapy is only widening. That combination — high per-member cost, broad eligibility, and rising demand — is why GLP-1 strategy sits on nearly every benefits leader's desk this year.
The GLP-1 cost stat block (dated survey data; refresh annually)
GLP-1 share of claims: 11.4% in 2026, up from 6.9% in 2023 (IFEBP/Becker's, 2026).
Nearly 8 in 10 large employers say GLP-1s are driving up their health care costs (Business Group on Health, 2026).
2026 employer health-benefit cost: >$18,500/employee, +6.7% — highest in 15 years (Mercer, 2026).
Rx spend +9.4% among large employers in 2025, GLP-1s a key driver (Mercer, 2026).
These are dated employer- and plan-survey figures that refresh annually. Treat them as directional market data, not permanent facts.
What employers actually cover in 2026
Coverage is common, but it is concentrated on the diabetes indication and it is not expanding. In the International Foundation of Employee Benefit Plans' 2026 survey (fielded June 2–12, representing more than 25 million lives), employers broke down this way:
Coverage approach | Share of employers, 2026 | 2025 |
|---|---|---|
GLP-1s for diabetes only | 60% | 55% |
GLP-1s for both diabetes and weight loss | 36% | 36% |
No GLP-1 coverage | 3% | 5% |
Not sure | 2% | 4% |
Source: IFEBP via Becker's Payer, 2026.
The headline is stability, not growth: coverage for both diabetes and weight loss held flat at 36% year over year, even as costs rose (CNBC). Among employers that cover GLP-1s for at least one indication, 45% also cover them for other FDA-approved uses beyond diabetes and weight loss (IFEBP/Becker's).
Looking ahead, the Business Group on Health found that among employers covering GLP-1s for weight management, 72% said they were likely to continue that coverage in 2027, while about 10% said they likely would not (Business Group on Health). The practical read: most employers are holding their position and tightening the rules around it, rather than adding or cutting the benefit wholesale.
The utilization-management playbook
Because dropping a popular, clinically effective drug class is unpopular and broad coverage is expensive, most employers have settled on a middle path: cover, but manage. The Business Group on Health reports that employers covering GLP-1s for obesity are increasingly layering on requirements "to ensure appropriateness and optimize outcomes for the patient and the plan" (Business Group on Health). The common levers:
Clinical-eligibility validation — confirming an appropriate diagnosis or objective biometric criteria (for example, a body-mass-index threshold) before approval.
Prior authorization — a documented clinical review before the plan pays, so therapy goes to members who meet the plan's criteria.
Program participation — requiring enrollment in a lifestyle or weight-management program alongside the medication.
Prescriber and formulary limits — steering prescriptions to specific providers and covering a narrower set of agents on the formulary.
Step therapy — asking members to try lower-cost alternatives first where clinically reasonable.
These tools filter therapy toward members most likely to benefit and away from requests that do not meet criteria; under a well-designed prior-authorization program, approval rates commonly land in the range of roughly 60–80% (IntuitionLabs analysis). Utilization management controls spend, but it does not by itself make a member successful on therapy — it governs the front door, not what happens after the prescription is filled. That gap is where a drug-only strategy tends to leak value.
The ROI question, graded honestly
Whether covering GLP-1s saves an employer money is the most-asked and least-settled question in this whole discussion, so it deserves an honest answer rather than a vendor's. The near-term picture is clear and the long-term picture is genuinely uncertain.
In the near term, the evidence is close to unanimous that GLP-1 coverage increases total employer health spending. The Peterson Health Technology Institute's December 2025 market-trend report is a useful neutral summary: a case study it cites found GLP-1 use reduced medical costs by roughly $560 per user per year — far outweighed by an average annual drug cost near $6,540, making short-term ROI negative for most employers (PHTI). Modeling from the Employee Benefit Research Institute, cited in the same report, found broad GLP-1 coverage can raise employer premiums by 6% to nearly 14% a year even with cost-sharing in place (PHTI).
The longer-term case is more hopeful but not proven. A 2026 Aon analysis found that sustained GLP-1 use among employees with type 2 diabetes was associated with about 6% lower medical cost growth after 30 months (PHTI summary); some analyses argue GLP-1s reduce costs over the long run (SHRM). The catch is timing: because average worker tenure is only about four years, the employer paying for the drug today may not be the one that eventually captures any downstream savings (PHTI).
So the honest bottom line: GLP-1s raise costs now, may moderate some costs later, and the payback window often outlasts how long an employee stays on your plan. Anyone promising guaranteed savings is selling past the evidence. The defensible strategy is to design for value — cover appropriately, manage utilization, and invest in the wraparound care that improves the odds a covered prescription actually produces a health outcome.
Where care navigation fits
A GLP-1 prescription is an input, not a result. Turning it into better metabolic health depends on the things that happen around the drug: an accurate diagnosis, an appropriate prescriber, adherence support, management of side effects, and coordination with the rest of a member's care. This is the difference between paying for a drug and running a program — and it is where care navigation as a benefit does work that pure coverage decisions and prior-authorization rules cannot.
Navigation complements a GLP-1 strategy in concrete ways. It helps members reach the right clinician for weight and metabolic care — often an obesity-medicine specialist, endocrinologist, or a primary care provider working with a dietitian — rather than defaulting to a fragmented search. It connects the medication to the conditions behind the spend, including the metabolic markers clinicians track such as HbA1c and fasting insulin. And it supports the appropriate-use and engagement strategies employers are already adopting — helping members meet eligibility and program requirements, stay adherent, and use the benefits the plan already offers — instead of relying on coverage cuts alone.
Importantly, navigation does not make coverage or clinical decisions. Who is eligible, what the formulary covers, and what a member should take are choices for the plan, its clinical and legal advisors, and the treating clinician. Navigation's role is to help members understand their options and reach appropriate care — the complement to a drug-only strategy, not a substitute for clinical judgment.
How to evaluate your 2026–2027 approach
For benefits leaders weighing coverage against cost, a few practical steps keep the decision grounded:
Model the spend with your own data. Use your plan's GLP-1 utilization and your PBM's actual net pricing rather than headline list prices; the claims share on your book is what matters.
Decide coverage and management together. Coverage breadth (diabetes-only vs. diabetes-plus-weight-loss) and your utilization-management design are one decision, not two.
Treat vendor ROI claims as vendor-reported. Ask for methodology, time horizon, and independent validation, and weigh them against neutral sources like PHTI.
Invest in the wraparound, not just the pill. Adherence, appropriate prescribing, and navigation to the right care are what move outcomes and protect the value of what you spend.
Coordinate with your advisors. Coverage design touches clinical, actuarial, and legal questions (including ADA considerations for obesity as a condition); make the call with them, not from a single survey.
Frequently asked questions
Do most employers cover GLP-1s in 2026?
Yes. In 2026, about 60% of employers cover GLP-1s for diabetes only and 36% cover them for both diabetes and weight loss, with only about 3% offering no coverage. Coverage for the combined diabetes-and-weight-loss indication held flat at 36% from 2025 to 2026 (IFEBP/Becker's, 2026).
How much do GLP-1s cost employers?
GLP-1s reached about 11.4% of employer health claims in 2026, up from 6.9% in 2023, and nearly 8 in 10 large employers say they are driving up costs. Average annual drug cost per GLP-1 user is roughly $6,540, which is why the drug class is a leading cost pressure even where only a minority of members use it (IFEBP/Becker's, 2026; Business Group on Health, 2026; PHTI, 2025).
Do GLP-1s save employers money?
Not in the near term for most employers. Independent modeling and case studies show GLP-1 coverage increases total spend now, with negative short-term ROI. Some longer-term analyses suggest cost moderation after several years, but average worker tenure of about four years often means the employer paying today may not capture later savings. Treat "GLP-1s save money" as unsettled, not proven (PHTI, 2025).
What is utilization management for GLP-1s?
It is the set of rules employers use to make sure GLP-1 coverage goes to appropriate members: clinical-eligibility or BMI criteria, prior authorization, required participation in a weight-management program, prescriber limits, formulary restrictions, and step therapy. These tools control spend and appropriateness; they do not, by themselves, ensure a member succeeds on therapy (Business Group on Health, 2026).
Should we cover GLP-1s for weight loss?
That is a plan-specific decision for your benefits, clinical, actuarial, and legal advisors — not a one-size answer. Weigh your own utilization and net pricing, your workforce's needs, the honest ROI evidence, and how you will support appropriate use. Many employers are choosing to cover with utilization management and wraparound care rather than expand or cut coverage outright.
How does care navigation help with GLP-1 costs?
Navigation supports the appropriate-use strategies employers are adopting — helping members meet eligibility requirements, reach the right prescriber and metabolic care, stay adherent, and use existing programs — so a covered prescription is more likely to produce a health outcome. It complements coverage and utilization-management decisions; it does not replace clinical or coverage judgment.
Key takeaways
GLP-1s are among the largest cost pressures on employer plans, at about 11.4% of claims in 2026, and nearly 8 in 10 large employers say they are raising costs.
Coverage is common but flat — 60% cover for diabetes only and 36% for diabetes plus weight loss — and most employers are managing the benefit rather than expanding or dropping it.
Utilization management (eligibility checks, prior authorization, program participation, prescriber and formulary limits, step therapy) is the dominant control lever.
The employer ROI of GLP-1 coverage is contested: costs rise now, may moderate later, and the payback window often outlasts employee tenure. Guaranteed-savings claims outrun the evidence.
A drug is not a program. Adherence, appropriate prescribing, and navigation to the right metabolic care are what turn a covered prescription into a health outcome.
For benefits leaders, brokers, and consultants: See how Manifold and Sidewalk deliver care navigation that makes a GLP-1 benefit work — not just pay for it. Request an employer demo or the benefits white paper at joinsidewalk.com.
This article is educational business and strategy information for employers and benefits professionals. It is not medical, legal, actuarial, or financial advice, and it does not diagnose, treat, or make coverage or eligibility recommendations for any individual. GLP-1 prescribing and clinical eligibility are decisions for treating clinicians; coverage, formulary, and benefits-design decisions should be made with your clinical, benefits, legal, and actuarial advisors. Cost and coverage figures are dated employer- and plan-survey data and refresh annually.
References
International Foundation of Employee Benefit Plans / Becker's Payer, Employer coverage of GLP-1s for diabetes, weight loss remains steady at 36%: Survey (2026). https://www.beckerspayer.com/research-analysis/employer-coverage-of-glp-1s-for-diabetes-weight-loss-remains-steady-at-36-survey/
Business Group on Health, GLP-1 Costs Loom Large for Employers, Forcing Challenging Coverage Decisions (2026). https://www.businessgrouphealth.org/newsroom/news-and-press-releases/press-releases/2026-glp-1-survey
Business Group on Health, 2026 Employer Health Care Strategy Survey (9% cost increase) (2026). https://www.businessgrouphealth.org/newsroom/news-and-press-releases/press-releases/2026-employer-health-care-strategy-survey
Mercer, US employers and workers face affordability crunch as health insurance cost is expected to exceed $18,500 per employee in 2026 (2026). https://www.mercer.com/en-us/about/newsroom/employers-and-workers-face-affordability-crunch-as-health-insurnace-cost-is-expected-to-exceed-18500-per-employee-in-2026/
Mercer, Employers prepare for the highest health benefit cost increase in 15 years (2026). https://www.mercer.com/en-us/insights/us-health-news/employers-prepare-for-the-highest-health-benefit-cost-increase-in-15-years/
CNBC, Employers aren't expanding coverage of GLP-1 obesity drugs: survey (July 8, 2026). https://www.cnbc.com/2026/07/08/employers-arent-expanding-coverage-of-glp-1-obesity-drugs-survey.html
Peterson Health Technology Institute (PHTI), Employer Approaches to GLP-1 Coverage — Market Trend Report (December 2025). https://phti.org/wp-content/uploads/sites/3/2025/12/PHTI-Employer-Approaches-to-GLP-1-Coverage-Market-Trend-Report.pdf
SHRM, GLP-1 Drugs Reduce Health Costs for Employers Over the Long Term (2026). https://www.shrm.org/topics-tools/news/benefits-compensation/glp-1-drugs-reduce-health-costs-employers-over-long-term
IntuitionLabs, GLP-1 Market Access: PBM Prior Auth & First-Fill Metrics (2026). https://intuitionlabs.ai/articles/glp-1-pbm-market-access-prior-authorization-benchmarks
Medically and editorially reviewed by the Manifold Health Clinical & Benefits Editorial Review. Published July 14, 2026 · Cost and coverage data refresh annually; last updated July 14, 2026.
